Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Delivery of Health Care, Integrated | 4 | 2023 | 535 | 0.880 |
Why?
|
| Mortality | 2 | 2020 | 116 | 0.760 |
Why?
|
| Renal Dialysis | 3 | 2022 | 57 | 0.750 |
Why?
|
| Kidney Failure, Chronic | 2 | 2020 | 151 | 0.740 |
Why?
|
| Chronic Pain | 1 | 2022 | 127 | 0.690 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 44 | 0.670 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 173 | 0.640 |
Why?
|
| Heart Failure | 2 | 2022 | 401 | 0.590 |
Why?
|
| Allergens | 1 | 2017 | 7 | 0.560 |
Why?
|
| Rhinitis, Allergic | 1 | 2017 | 5 | 0.560 |
Why?
|
| Hospitalization | 3 | 2022 | 804 | 0.530 |
Why?
|
| Hypertension | 4 | 2023 | 469 | 0.480 |
Why?
|
| Asthma | 1 | 2017 | 400 | 0.440 |
Why?
|
| Atherosclerosis | 2 | 2023 | 52 | 0.370 |
Why?
|
| Humans | 20 | 2023 | 17314 | 0.340 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 224 | 0.310 |
Why?
|
| Risk | 3 | 2020 | 496 | 0.310 |
Why?
|
| Stroke | 2 | 2022 | 309 | 0.290 |
Why?
|
| Retrospective Studies | 8 | 2022 | 2415 | 0.270 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 532 | 0.270 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2022 | 302 | 0.260 |
Why?
|
| Female | 14 | 2023 | 12396 | 0.260 |
Why?
|
| Male | 11 | 2023 | 9804 | 0.260 |
Why?
|
| Prehypertension | 2 | 2016 | 21 | 0.240 |
Why?
|
| Risk Factors | 6 | 2023 | 3258 | 0.240 |
Why?
|
| Cohort Studies | 4 | 2020 | 2514 | 0.240 |
Why?
|
| Middle Aged | 10 | 2023 | 7836 | 0.230 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 44 | 0.220 |
Why?
|
| Logistic Models | 3 | 2020 | 879 | 0.200 |
Why?
|
| Health Literacy | 1 | 2022 | 38 | 0.190 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 1925 | 0.190 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 53 | 0.190 |
Why?
|
| Drug Prescriptions | 1 | 2022 | 146 | 0.180 |
Why?
|
| Aged | 7 | 2020 | 6084 | 0.180 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 701 | 0.180 |
Why?
|
| Adult | 6 | 2023 | 7500 | 0.180 |
Why?
|
| Nadolol | 1 | 2020 | 1 | 0.170 |
Why?
|
| Bisoprolol | 1 | 2020 | 1 | 0.170 |
Why?
|
| Propranolol | 1 | 2020 | 4 | 0.170 |
Why?
|
| Atenolol | 1 | 2020 | 6 | 0.170 |
Why?
|
| Metoprolol | 1 | 2020 | 6 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 15 | 0.170 |
Why?
|
| Protective Factors | 1 | 2020 | 32 | 0.170 |
Why?
|
| Labetalol | 1 | 2020 | 9 | 0.170 |
Why?
|
| Politics | 1 | 2020 | 10 | 0.170 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 53 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 84 | 0.160 |
Why?
|
| Cause of Death | 1 | 2020 | 176 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 245 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2020 | 134 | 0.150 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 154 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 1280 | 0.150 |
Why?
|
| Blood Pressure | 2 | 2023 | 275 | 0.150 |
Why?
|
| Catheters, Indwelling | 1 | 2018 | 1 | 0.140 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2018 | 2 | 0.140 |
Why?
|
| Peritoneal Dialysis | 1 | 2018 | 6 | 0.140 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 40 | 0.140 |
Why?
|
| Infant, Newborn | 2 | 2017 | 805 | 0.140 |
Why?
|
| Vehicle Emissions | 1 | 2017 | 23 | 0.140 |
Why?
|
| Immunization | 1 | 2017 | 69 | 0.130 |
Why?
|
| Air Pollutants | 1 | 2017 | 54 | 0.130 |
Why?
|
| Humerus | 1 | 2016 | 1 | 0.120 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2016 | 22 | 0.120 |
Why?
|
| Lipoproteins | 1 | 2015 | 13 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 47 | 0.120 |
Why?
|
| Cholesterol | 1 | 2015 | 82 | 0.120 |
Why?
|
| Eclampsia | 1 | 2015 | 12 | 0.120 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2015 | 6 | 0.120 |
Why?
|
| Community Health Services | 1 | 2016 | 79 | 0.120 |
Why?
|
| Pre-Eclampsia | 1 | 2015 | 40 | 0.120 |
Why?
|
| Fractures, Bone | 1 | 2016 | 92 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 112 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 1151 | 0.110 |
Why?
|
| Infant | 1 | 2017 | 1161 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2016 | 161 | 0.110 |
Why?
|
| Curettage | 1 | 2013 | 1 | 0.100 |
Why?
|
| Electrocoagulation | 1 | 2013 | 3 | 0.100 |
Why?
|
| Child, Preschool | 1 | 2017 | 1380 | 0.100 |
Why?
|
| Young Adult | 4 | 2023 | 2465 | 0.100 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2013 | 24 | 0.100 |
Why?
|
| United States | 2 | 2020 | 3866 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 58 | 0.100 |
Why?
|
| Femoral Fractures | 1 | 2012 | 23 | 0.100 |
Why?
|
| Osteoporotic Fractures | 1 | 2012 | 40 | 0.090 |
Why?
|
| Diphosphonates | 1 | 2012 | 63 | 0.090 |
Why?
|
| Diabetes, Gestational | 1 | 2015 | 311 | 0.090 |
Why?
|
| Child | 1 | 2017 | 2403 | 0.090 |
Why?
|
| Incidence | 3 | 2023 | 1266 | 0.080 |
Why?
|
| California | 4 | 2020 | 2311 | 0.080 |
Why?
|
| Adolescent | 3 | 2022 | 3538 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2023 | 1076 | 0.060 |
Why?
|
| Time Factors | 2 | 2018 | 1039 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2022 | 8 | 0.050 |
Why?
|
| Acute Disease | 1 | 2022 | 144 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2023 | 188 | 0.040 |
Why?
|
| Pregnancy | 2 | 2016 | 1463 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 287 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 499 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 560 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 840 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 153 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 259 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2018 | 149 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2015 | 5 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2015 | 9 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 32 | 0.030 |
Why?
|
| Suburethral Slings | 1 | 2015 | 1 | 0.030 |
Why?
|
| Urodynamics | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 69 | 0.030 |
Why?
|
| Triglycerides | 1 | 2015 | 83 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2015 | 107 | 0.030 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 41 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 112 | 0.030 |
Why?
|
| Weight Gain | 1 | 2016 | 156 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 304 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2015 | 169 | 0.030 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 407 | 0.030 |
Why?
|
| Biopsy | 1 | 2013 | 82 | 0.030 |
Why?
|
| Office Visits | 1 | 2013 | 73 | 0.030 |
Why?
|
| Diaphyses | 1 | 2012 | 5 | 0.030 |
Why?
|
| Radiography | 1 | 2012 | 36 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 342 | 0.020 |
Why?
|
| Bone Density | 1 | 2012 | 94 | 0.020 |
Why?
|
| Hip Fractures | 1 | 2012 | 71 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 1226 | 0.020 |
Why?
|
Concepts
(125)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(11)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->